ArticleMolecular and clinical oncology2025
Extended progression-free survival after combination treatment with anlotinib and S-1 in refractory advanced esophageal cancer: A case report.
Jinsong Yang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.